PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
1.050
+0.010 (0.96%)
Nov 4, 2024, 4:00 PM EST - Market closed
PAVmed Employees
PAVmed had 107 employees as of December 31, 2023. The number of employees decreased by 17 or -13.71% compared to the previous year.
Employees
107
Change (1Y)
-17
Growth (1Y)
-13.71%
Revenue / Employee
$35,785
Profits / Employee
-$629,430
Market Cap
10.93M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Star Equity Holdings | 171 |
Turnstone Biologics | 80 |
RedHill Biopharma | 53 |
Senti Biosciences | 48 |
Vincerx Pharma | 42 |
Dominari Holdings | 28 |
Edesa Biotech | 16 |
Kiora Pharmaceuticals | 12 |
PAVM News
- 4 days ago - PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - PRNewsWire
- 5 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - PRNewsWire
- 20 days ago - Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - PRNewsWire
- 25 days ago - PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care - PRNewsWire
- 26 days ago - Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - PRNewsWire
- 27 days ago - Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 - PRNewsWire
- 5 weeks ago - American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test - PRNewsWire
- 7 weeks ago - PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements - PRNewsWire